Black Diamond Therapeutics, Inc. (BDTX)

Market Cap	179.31M +100.3%
Revenue (ttm)	70.00M
Net Income	22.37M
EPS	0.39
Shares Out	57.29M
PE Ratio	8.03
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	428,306
Open	3.040
Previous Close	3.060
Day's Range	2.985 - 3.165
52-Week Range	1.310 - 4.940
Beta	3.39
Analysts	Strong Buy
Price Target	9.50 (+203.51%)
Earnings Date	May 11, 2026

About BDTX

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 30, 2020
• Employees: 21
• Stock Exchange: NASDAQ
• Ticker Symbol: BDTX

Analyst Summary

According to 7 analysts, the average rating for BDTX stock is "Strong Buy." The 12-month stock price target is $9.5, which is an increase of 203.51% from the latest price.

Price Target

$9.5

(203.51% upside)

Analyst Consensus: Strong Buy